Literature DB >> 20562597

Current and future therapeutic options for the management of gout.

Andrew Whelton1.   

Abstract

The incidence of gout and the clinical manifestation of hyperuricemia continue to rise. In addition to painful acute attacks, chronic gout can lead to the development of crystal arthropathy, tophi, and renal lithiasis, coincidental with declines in quality of life. As a greater appreciation for the associations between hyperuricemia, gout, and certain comorbidities, such as renal impairment and cardiovascular diseases, grows, so does the search for new therapeutic options to both alleviate the painful symptoms of acute gout attacks and reduce the underlying hyperuricemia. This manuscript reviews the pathophysiology of hyperuricemia and gout, and associated comorbidities, and then discusses traditional therapeutic options, newly available agents, and future targets for pharmacologic management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20562597     DOI: 10.1097/MJT.0b013e3181df8ad2

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  5 in total

Review 1.  Tophaceous gout in the elderly: a clinical case review.

Authors:  Francesco Bolzetta; Nicola Veronese; Enzo Manzato; Giuseppe Sergi
Journal:  Clin Rheumatol       Date:  2012-02-25       Impact factor: 2.980

Review 2.  PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.

Authors:  Ellen M McDonagh; Caroline F Thorn; John T Callaghan; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-09       Impact factor: 2.089

3.  African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

Authors:  Alvin F Wells; Patricia A MacDonald; Solomon Chefo; Robert L Jackson
Journal:  BMC Musculoskelet Disord       Date:  2012-02-09       Impact factor: 2.362

4.  Oral uricase eliminates blood uric acid in the hyperuricemic pig model.

Authors:  Paulina Szczurek; Nadia Mosiichuk; Jarosław Woliński; Tetiana Yatsenko; Danica Grujic; Liudmyla Lozinska; Marek Pieszka; Ewa Święch; Stefan Grzegorz Pierzynowski; Kateryna Goncharova
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 5.  Tumor lysis syndrome in childhood malignancies.

Authors:  Wing Lum Cheung; Kam Lun Hon; Cheuk Man Fung; Alexander Kc Leung
Journal:  Drugs Context       Date:  2020-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.